Campbell & Co Investment Adviser’s Rhythm Pharmaceuticals RYTM Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,958	Closed	-$518K	–	1321
2026 Q1	$518K	Buy	+5,958	New	+$579K	0.03%	734
2024 Q4	–	Sell	-4,184	Closed	-$219K	–	1323
2024 Q3	$219K	Buy	+4,184	New	+$200K	0.02%	1000
2024 Q2	–	Sell	-16,331	Closed	-$708K	–	1309
2024 Q1	$708K	Buy	16,331 +5,589	+52%	+$245K	0.06%	545
2023 Q4	$494K	Buy	+10,742	New	+$339K	0.04%	719
2023 Q1	–	Sell	-19,535	Closed	-$569K	–	1005
2022 Q4	$569K	Buy	+19,535	New	+$502K	0.14%	250

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Campbell & Co Investment Adviser's RYTM Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 5,958 shares — an estimated $518K sold.

Campbell & Co Investment Adviser first reported a position in RYTM in Q4 2022 and held it in 5 quarters. The position peaked at $708K in Q1 2024. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Campbell & Co Investment Adviser reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 5,958 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $518K.
Campbell & Co Investment Adviser first reported a position in Rhythm Pharmaceuticals in Q4 2022 and held it in 5 quarters.
Campbell & Co Investment Adviser's Rhythm Pharmaceuticals position peaked at $708K in Q1 2024.
303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.